申请人:SmithKline Beecham p.l.c.
公开号:US20020143029A1
公开(公告)日:2002-10-03
Compounds of formula (I) and pharmaceutically acceptable salts and solvates:
1
where R
1
is hydrogen, C
1-6
alkyl (optionally substituted by hydroxy or C
1-4
alkoxy), phenyl-C
1-4
alkyl-, C
1-6
alkenyl, C
1-6
alkynyl;
R
2
is hydrogen or up to three substituents selected from halogen, NO
2
, CN, N
3
, CF
3
O—, CF
3
S—, CF
3
CO—, C
1-6
alkyl, C
1-6
alkenyl, C
1-6
alkynyl, C
1-6
perfluoroalkyl, C
3-6
cycloalkyl, C
3-6
cycloalkyl-C
1-4
alkyl-, C
1-6
alkylO—, C
1-6
alkylCO—, C
3-6
cycloalkylO—, C
3-6
cycloalkylCO—, C
3-6
cycloalkyl-C
1-4
alkylO—, C
3-6
cycloalkyl-C
1-4
alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C
1-4
alkyl-, C
1-6
alkylS—, C
1-6
alkylSO
2
—, (C
1-4
alkyl)
2
NSO
2
—, (C
1-4
alkyl)NHSO
2
—, (C
1-4
alkyl)
2
NCO—, (C
1-4
alkyl)NHCO— or CONH
2
;
or —NR
5
R
6
where R
5
is hydrogen or C
1-4
alkyl, and
R
6
is hydrogen, C
1-4
alkyl, formyl, —CO
2
C
1-4
alkyl or —COC
1-4
alkyl;
or two R
2
groups together form a carbocyclic ring that is saturated or unsaturated.
R
3
groups and R
4
groups are each independently hydrogen or C
1-6
alkyl and/or the two R
3
groups and/or the two R
4
groups together form a C
3-6
spiroalkyl group, provided that at least one R
3
or R
4
group is not hydrogen; and
X is selected from hydrogen, halogen, cyano, alkyl and alkoxy. are useful in the treatment and prophylaxis of epilepsy, migraine, and other disorders.
公式(I)化合物及其药学上可接受的盐和溶剂化合物:其中R1为
氢、C1-6烷基(可选地被羟基或C1-4烷
氧基取代)、
苯基-C1-4烷基、C1-6
烯基、C1-6炔基;R2为
氢或最多三个取代基,所选自卤素、
NO2、CN、N3、
CF3O—、
CF3S—、CF3CO—、C1-6烷基、C1-6
烯基、C1-6炔基、C1-6
全氟烷基、C3-6
环烷基、C3-6
环烷基-C1-4烷基、C1-6烷
氧基、C1-6烷基CO—、C3-6
环烷基烷
氧基、C3-6
环烷基CO—、C3-6
环烷基-C1-4烷
氧基、C3-6
环烷基-C1-4烷基CO—、
苯基、
苯氧基、苄
氧基、
苯甲酰基、
苯基-C1-4烷基、C1-6烷基S—、C1-6烷基SO2—、(C1-4烷基)2NSO2—、(C1-4烷基)NHSO2—、(C1-4烷基)2NCO—、(C1-4烷基)NHCO—或CONH2;或—NR5R6,其中R5为
氢或C1-4烷基,R6为
氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基;或两个R2基共同形成一个饱和或不饱和的
碳环。R3基和R4基各自独立地为
氢或C1-6烷基,或两个R3基和/或两个R4基共同形成一个C3-6螺
环烷基,前提是至少有一个R3或R4基不是
氢;X选自
氢、卤素、
氰基、烷基和烷
氧基。这些化合物对于治疗和预防癫痫、偏头痛和其他疾病是有用的。